ProCE Banner Activity

ALCANTARA: Blinatumomab Shows Activity in R/R Ph-Positive B-Precursor ALL

Slideset Download
Conference Coverage
Early data suggest that blinatumomab monotherapy has antileukemic activity in Ph+ B-precursor ALL after failure on TKI therapy.

Released: December 10, 2015

Expiration: December 08, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen